Watch PAHC. Know when insiders buy.
One email the day a filing lands. Free.
PAHC
PHIBRO ANIMAL HEALTH CORP
32.96
−2.44 −6.89%
USD · close Nov 6
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
55
WATCH · shorts 55
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $2.3BP/E 13.5DIV YIELD —FCF YIELD 0.43%REV TTM $1.5B +17.1%NET INCOME $99.7M +106.6%NET DEBT $559.1M52W 28.52 – 59.58SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q4 2026 · Jun 30derived | $396.7M | +4.8% | 33.9% | $48.2M | $21.7M | +26.0% | 0.53 | $24.1M | $18.9M | $5.2M | Aug 26 |
| Q3 2026 · Mar 31 | $383.5M | +10.3% | 32.8% | $44.7M | $24M | +15.1% | 0.59 | $16.2M | $15.3M | $890K | May 6 |
| Q2 2026 · Dec 31 | $373.9M | +20.9% | 35.5% | $50.3M | $27.5M | +762.1% | 0.67 | $19.4M | $11.1M | $8.3M | May 6 |
| Q1 2026 · Sep 30 | $363.9M | +39.7% | 32.9% | $51.3M | $26.5M | +280.3% | 0.65 | $9.3M | $13.8M | −$4.5M | May 6 |
| Q4 2025 · Jun 30derived | $378.7M | +38.6% | 29.0% | $33.7M | $17.2M | +2190.4% | 0.43 | $21.3M | $13.1M | $8.1M | Aug 26 |
| Q3 2025 · Mar 31 | $347.8M | +32.1% | 30.1% | $33.5M | $20.9M | +148.4% | 0.51 | $43.2M | $7.7M | $35.4M | May 6 |
| Q2 2025 · Dec 31 | $309.3M | +23.7% | 32.9% | $25.5M | $3.2M | +150.0% | 0.08 | $3.1M | $7.8M | −$4.7M | May 6 |
| Q1 2025 · Sep 30 | $260.4M | +12.6% | 32.1% | $17.7M | $7M | — | 0.17 | $12.6M | $9.6M | $3M | May 6 |
| Q4 2024 · Jun 30derived | $273.2M | — | 31.9% | $18.4M | $752K | — | 0.02 | $28.4M | $13.1M | $15.4M | Aug 26 |
| Q3 2024 · Mar 31 | $263.2M | — | 30.2% | $19.9M | $8.4M | — | 0.21 | $11.4M | $9.7M | $1.7M | May 7 |
| Q2 2024 · Dec 31 | $249.9M | — | 31.5% | $15.7M | $1.3M | — | 0.03 | $31.6M | $11M | $20.6M | May 7 |
| Q1 2024 · Sep 30 | $231.3M | — | 29.3% | −$726K | −$8M | — | -0.20 | $16.2M | $7.5M | $8.7M | May 7 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2026 · to Jun 30 | $1.5B | 33.8% | $194.4M | $99.7M | 6.6% | 2.43 | $69M | $59.1M | $9.9M | — | $19.5M |
| FY2025 · to Jun 30 | $1.3B | 30.9% | $110.5M | $48.3M | 3.7% | 1.19 | $80.1M | $38.3M | $41.8M | — | $19.4M |
| FY2024 · to Jun 30 | $1B | 30.8% | $53.3M | $2.4M | 0.2% | 0.06 | $87.6M | $41.2M | $46.4M | — | $19.4M |
| FY2023 · to Jun 30 | $977.9M | 30.5% | $71.8M | $32.6M | 3.3% | 0.81 | $13.3M | $51.8M | −$38.5M | — | $19.4M |
| FY2022 · to Jun 30 | $942.3M | 30.3% | $79M | $49.2M | 5.2% | 1.21 | $31.6M | $37M | −$5.4M | — | $19.4M |
| FY2021 · to Jun 30 | $833.4M | 32.6% | $74.9M | $54.4M | 6.5% | 1.34 | $48.3M | $29.3M | $19M | — | $19.4M |
Every number comes from PHIBRO ANIMAL HEALTH CORP's own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.